The racketeering action, which is filed in the U.S. District Court for the District of Columbia, charges that Johnson & Johnson conspired to criminally influence the Commissioner of the Food & Drug Administration to mislabel and misbrand Levaquin.
The case charges that J&J defrauded consumers in order to acquire and reap financial gain, by:
- Driving up or maintaining the price of shares of Johnson & Johnson stock.
- Increasing the financial holdings and value of Johnson & Johnson stock held by defendant Renaissance Technologies, L.L.C.
- Increasing defendant Renaissance Technologies, L.L.C.’s corporate income thereby increasing financial remuneration and gain to defendants Peter F. Brown, Robert L. Mercer, and James H. Simons by virtue of FDA Commissioner Dr. Margaret Hamburg ’s marriage to Peter F. Brown.
- Increasing corporate income of the officers of Johnson & Johnson, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, and Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Avoiding potential lawsuits against Johnson & Johnson.
- Increasing the combined wealth of defendants FDA Commissioner Dr. Margaret Hamburg and her husband, Peter F. Brown.
The FDA attributes 5,000 deaths and 8,000 injuries to Levaquin. Levaquin is considered dangerous to human health, unfit and unsuitable to be marketed as labeled and sold, misbranded, falsely advertised, promoted for off-label use, and introduced into interstate commerce. Levaquin causes mitochondrial toxicity, certain neuropsychiatric adverse events, increased risk of acquiring potentially fatal Carbapenem-Resistant Enterobacteriaceae, Fluoroquinolone-Associated Disability (“FQAD”), a term the FDA coined in 2015.
Johnson & Johnson has sold dangerous drugs and products including Tylenol, Motrin, Zyrtec, Benadryl, Risperdal, Invega, DePuy hip implants, Transvaginal Mesh, Xarelto, and Invokana. Multi-district litigation docket MDL 1943 has been organized against Johnson & Johnson in federal court in Minnesota.